KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.75

Proof of concept of physiologically based pharmacokinetic modelling in paediatric acute lymphoblastic leukaemia.

Thomas Bauch, Georg Hempel

Br J Haematol 204(6) 2324-2331

PMID38494194
PMCID-
DOI10.1111/bjh.19410
发表日期2024-03-17
入排依据:The record describes a proof-of-concept pharmacokinetic modelling study within the context of phase II/III oncology trials. While it meets the oncology, human, randomized, and definitive phase criteria, the primary outcome reported is pharmacokinetic parameters, not the required survival, progression, or other time-to-event efficacy endpoints. Therefore, it is excluded.
摘要

摘要

Physiologically based pharmacokinetic (PBPK) modelling is an alternative modelling technique that is increasingly used in pharmacokinetics. Due to its nature, it can be complementarily employed to population pharmacokinetics, especially when it comes to small population size. Here, we report the proof of concept of its application to accurately describe the pharmacokinetics of a recombinant L-asparaginase in paediatric patients with acute lymphoblastic leukaemia. Data from two randomized, double-blind, phase II/III clinical studies (MC-ASP.4/ALL; MC-ASP.5/ALL) were included to setup and evaluate the final model, respectively. Final population values for basic pharmacokinetic parameters were calculated (clearance: 0.0569 L/h/19.5 kg, volume of distribution: 1.251 L, half-life: 18.5 h, trough concentration: 140.9 IU/L). Pharmacokinetic parameter prediction as well as predictive performance of the model proofed to be comparable to a separately developed population pharmacokinetic model with 13% deviation in predicted median L-asparaginase trough levels. To the best of our knowledge, this is the first whole-body PBPK model of a non-antibody therapeutic protein.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。